The next generation immune checkpoint inhibitors and stimulators market is estimated to be worth USD 12.5 billion in 2030

Health & Fitness / Biotech, Health, Pharma, Research / By /

Therapies targeting novel inhibitory and stimulatory immune checkpoints have been shown to possess substantial therapeutic potential, both as monotherapies and in combination with other interventions, across multiple disease interventions

Advertisements

 

is pleased to announce the publication of its recent study, titled, “Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030.”

 

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of drug developers engaged in the development of next generation immune checkpoint modulators.
  • A detailed analysis of more than 590 completed, ongoing and planned clinical studies of next generation immune checkpoint inhibitors and stimulators.
  • Detailed profiles of developers of next generation immune checkpoint modulators (shortlisted on the basis of the number of pipeline products).
  • An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects.
  • An analysis of the partnerships that have been established in this domain, in the recent past.
  • A competitiveness analysis of biological targets, featuring insightful pictorial summaries and representations.
  • An analysis of the initiatives of big biopharma players engaged in this domain.
  • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
  • Target Disease Indication
  • Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Colorectal Cancer
  • Head and Neck Cancer
  • Lung Cancer
  • Lupus Nephritis
  • Melanoma
  • Multiple Myeloma
  • Primary Sjögren’s Syndrome
  • Others
  • Target Immune Checkpoint
  • B7-H3
  • CD38
  • CD40
  • CD47
  • Others
  • Mechanism of Action
  • Inhibitory
  • Stimulatory
  • Therapeutic Modality
  • Monoclonal Antibody
  • Small Molecule
  • Type of Therapy
  • Monotherapy
  • Combination Therapy
  • Route of Administration
  • Intravenous
  • Subcutaneous
  • Others
  • Key Geographical Region
  • North America
  • Europe
  • Asia-Pacific and the Rest of the World

 

Key companies covered in the report

  • Bristol Myers Squibb
  • GlaxoSmithKline
  • Incyte
  • Novartis
  • Trillium Therapeutics

 

For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

 

Other Recent Offerings

 

  • Transcripts of interviews held with the following senior level representatives of stakeholder companies
  • Jean-Yves Ortholand, Co-founder & Chief Executive Officer, Edelris
  • Björn Walse, Chief Executive Officer, SARomics Biostructures

Related Posts